Reports Third-Quarter Diluted EPS of $0.88 on a GAAP Basis, a Decrease of 12.0 Percent; Adjusted Diluted EPS of $3.00 , an Increase of ...

For the fiscal year ending Dec 2024 , the consensus EPS* forecast has remained the same over the past week at 10.95 and increased over the past month from 10.85 ...

30 окт. 2024 г. · The company reported third-quarter adjusted earnings of $3 per share on sales of $14.5 billion, compared with estimates of $2.91 per share on ...

30 окт. 2024 г. · Diluted EPS in the third quarter was $0.88 on a GAAP basis. Adjusted diluted EPS, excluding specified items, was $3.00. These results include an ...

Find the latest AbbVie Inc. (ABBV) stock quote, history, news and other vital information to help you with your stock trading and investing. Why AbbVie Stock Was... · AbbVie's Emraclidine For... · AbbVie announces 2025...

25 июл. 2024 г. · Worldwide net revenues were $14.462 billion, an increase of 4.3 percent on a reported basis, or 5.6 percent on an operational basis. Global ...

Оценка 4,0 (19 975) AbbVie (ABBV) will release its next earnings report on Jan 28, 2025. In the last quarter AbbVie reported $2.92 EPS in relation to $3 expected by the market.

AbbVie reported $3 in EPS Earnings Per Share for its fiscal quarter ending in September of 2024. Data for AbbVie | ABBV - EPS Earnings Per Share including ...

Explore AbbVie earnings insights, including the latest release, EPS and revenue forecasts to stay updated on the company's financial performance.